Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies
June 23 2021 - 8:00AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that Greg Sukay has joined the company as Vice President,
Manufacturing and Process Technologies. Mr. Sukay, who brings more
than 25 years of experience in biopharmaceutical operations, will
oversee Arcutis’ external manufacturing and process development for
its pipeline of medical dermatology programs.
“We welcome Greg at an exciting time for our company, as we
advance closer than ever to bringing our novel products to patients
with immune-driven skin disorders,” said Frank Watanabe, Arcutis’
President and Chief Executive Officer. “With his extensive
background in product development, operations, and manufacturing,
Greg will be an integral leader as we scale our programs to a
commercial stage, especially in preparation for the anticipated
launch of topical roflumilast.”
Topical roflumilast, Arcutis’ lead product candidate, is being
studied in cream and foam formulations as a potential
transformative treatment for chronic plaque psoriasis, atopic
dermatitis, scalp psoriasis, and seborrheic dermatitis.
“I am honored to join Arcutis at such a significant stage and to
play a role in bringing the company’s vision to life,” Mr. Sukay
said. “Topical roflumilast is just the first example of how we are
moving forward with our mission to revitalize the standard of care
for dermatological diseases. Through state-of-the-art manufacturing
and process development, I look forward to helping bring innovative
new therapies to patients in need.”
Prior to joining Arcutis, Mr. Sukay spent more than 22 years at
Amgen, where he most recently served as Executive Director of Amgen
Contract Manufacturing, overseeing a global multi-million dollar
contract manufacturing network. He also spent six years as Plant
Manager and Executive Director of Amgen Singapore. He holds over 25
years of drug development experience in various roles, including
director of process development and principal engineer. Greg earned
his B.S. in Chemical Engineering from Purdue University.
About ArcutisArcutis Biotherapeutics, Inc.
(Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on
developing and commercializing treatments for unmet needs in
immune-mediated dermatological diseases and conditions, or
immuno-dermatology. The company is leveraging recent advances in
immunology and inflammation to develop differentiated therapies
against biologically validated targets to solve persistent
treatment challenges in serious diseases of the skin. Arcutis’
robust pipeline includes four novel drug candidates currently
in development for a range of inflammatory dermatological
conditions. The company’s lead product candidate, topical
roflumilast, has the potential to revitalize the standard of care
for plaque psoriasis, atopic dermatitis, scalp psoriasis, and
seborrheic dermatitis. For more information,
visit www.arcutis.com or follow the company
on LinkedIn and Twitter.Forward-Looking
StatementsThis press release contains "forward-looking"
statements, including, among others, statements regarding the
potential for roflumilast to revolutionize the standard of care in
plaque psoriasis and other inflammatory dermatological conditions.
These statements involve substantial known and unknown risks,
uncertainties and other factors that may cause our actual results,
levels of activity, performance, or achievements to be materially
different from the information expressed or implied by these
forward-looking statements and you should not place undue reliance
on our forward-looking statements. Risks and uncertainties that may
cause our actual results to differ include risks inherent in the
clinical development process and regulatory approval process, the
timing of regulatory filings, and our ability to defend our
intellectual property. For a further description of the risks and
uncertainties applicable to our business, see the "Risk Factors"
section of our Form 10-K filed with U.S. Securities and Exchange
Commission (SEC) on February 16, 2021, as well as any subsequent
filings with the SEC. We undertake no obligation to revise or
update information herein to reflect events or circumstances in the
future, even if new information becomes available.
Investor and Media Contact:ir@arcutis.com
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024